SOURCE: Vicor Technologies, Inc.

June 10, 2008 09:15 ET

Vicor Technologies Announces New Addition to Scientific Advisory Board

BOCA RATON, FL--(Marketwire - June 10, 2008) - Vicor Technologies, Inc. (OTCBB: VCRT), focused on the commercialization of the PD2i Cardiac Analyzer, a patented device utilized in the risk stratification of patients for Sudden Cardiac Death (SCD), announces the addition of David Chazanovitz to its Scientific Advisory Board.

Mr. Chazanovitz currently serves as President, CEO and a Director of Alveolus, Inc., a medical device company dedicated to the development and commercialization of non-vascular stents. Previously, he served as Chief Executive Officer of Cambridge Heart, Inc., a publicly traded company, from February 2001 through October 2006 and as the President and a Director of Cambridge Heart from October 2000 through October 2006, including service as the Chairman of the Board of Directors from July 2004 to October 2006.

Commenting on the appointment, Vicor President and CEO, Mr. David H. Fater, stated, "We are delighted and gratified to have an individual with Mr. Chazanovitz's professional experience join our Scientific Advisory Board. His background in the medical device industry, in general, and with Cambridge Heart, in particular, provides him with a unique perspective with which to assist Vicor in the commercialization and expansion of our PD2i Cardiac Analyzer platform technology."

"We believe his advice and insight will make very meaningful contributions to Vicor as we face the same challenges that he has already successfully overcome in the same medical device space as ours, including such important areas as the FDA approval process and obtaining reimbursement for physicians. He brings both a business and scientific perspective to join other distinguished members of the Vicor team. We are extremely pleased to be able to access him as a knowledgeable resource," concluded Mr. Fater.

Mr. Chazanovitz joins the other members of Vicor's Scientific Advisory Board who include:

--  Edward Wiesmeier, M.D., Clinical Professor, Obstetrics & Gynecology,
    UCLA. Dr. Wiesmeier was formerly the Assistant Vice Chancellor for Student
    Health and Development at UCLA and currently serves as Chairperson of the
--  Mark E. Josephson, M.D., Chief of Cardiology at Beth Israel Deaconess
    Medical Center, a major patient care, research and teaching affiliate of
    Harvard Medical School and the author of "Clinical Cardiac
    Electrophysiology," the fundamental textbook in the field.
--  Hein J. J. Wellens, M.D., Professor and Chairman of the Department of
    Cardiology at Academisch Ziekenhuis Maastricht in Amsterdam, the
    Netherlands.  He is a Director of the Interuniversity Cardiology Institute
    of the Netherlands and is a member of the Netherlands Academy of Arts and
    Sciences.  He also has an appointment of visiting lecturer at Harvard
    Medical School.
--  Richard M. Luceri, M.D., F.A.C.C., recently retired Director of the
    Interventional Arrhythmia Center at Holy Cross Hospital, Fort Lauderdale,
    FL as well as a clinical investigator in the MADIT II (MultiCenter
    Automatic Defibrillator Implantation Trial) and author SCDHeFT (Sudden
    Cardiac Death Heart Failure Trial).
--  Robert G. Hauser, MD, FACC, FHRS, Senior Consulting Cardiologist at
    the Minneapolis Heart Institute and Chairman of the Cardiovascular Services
    Division at Abbott Northwestern Hospital.   He was the Chief Executive
    Officer of Cardiac Pacemakers, Inc., from 1988-1992, then a subsidiary of
    Eli Lilly, later acquired by Guidant Corporation.
--  Jules T. Mitchel, M.B.A., Ph.D., the Founder of Target Health, Inc., a
    full-service contract research organization supporting all aspects of
    pharmaceutical drug and device development.
--  Edward F. Lundy, M.D., Ph.D. is Chief of Cardiothoracic Surgery at the
    Active International Cardiovascular Institute at Good Samaritan Hospital in
    Suffern, New York. In addition to his M.D. from the University of Michigan,
    Dr. Lundy also received a Ph.D. from that institution in Physiology with a
    primary focus on altered-state physiologies such as hibernation.
--  Jonathan Kaplan, M.D., M.P.H., Medical Director for Fidelis Care New
    York (one of the largest government program-based health plans in New York
    State), and formerly the Corporate Medical Director for Excellus Blue Cross
    Blue Shield.
--  Hank Lubin, M.D., a practicing physician with Hightstown Medical
    Associates, PA (formerly affiliated with the University of Pennsylvania
    Health System), and currently a Clinical Associate Professor at The
    University of Pennsylvania School of Medicine.
--  Ariel D. Soffer, M.D., F.A.C.C., Chief of Medicine, Hollywood Medical
    Center, Hollywood, FL. President/C.E.O. Florida Institute for
    Cardiovascular Care (Healthworx).
--  Frank S. Caruso, Ph.D., the Founder of two successful start-up
    pharmaceutical companies (Algos Pharmaceutical Corporation and Roberts
    Pharmaceutical Corporation). He has more than 30 years' experience
    directing worldwide clinical/pharmacological research and biological
    evaluation programs involving licensing and drug development research
--  David Fertel, D.O., a Clinical Professor of Surgery at Michigan State
    University, as well as a practicing Board Certified Thoracic and
    Cardiovascular surgeon in Michigan.

About Sudden Cardiac Death (SCD)

SCD (the leading killer in the U.S. with over 500,000 annual deaths) is a fatal arrhythmic event and is different than a heart attack. A heart attack is analogous to a plumbing problem, where the blood supply to a part of the heart is choked off, leading to the death of that portion of the heart muscle. SCD is theorized to be caused by a breakdown of the normal neurological communication pattern between the heart and brain, more like an electrical problem, which can lead to a rapid, life threatening heart rhythm that is usually fatal within minutes, if untreated. It is swift, unexpected, and often has no advance warning or symptoms.

About Vicor Technologies, Inc.

Vicor's medical device, the PD2i Cardiac Analyzer, is based on a patented, proprietary algorithm. Vicor believes the PD2i Cardiac Analyzer accurately risk stratifies patients who are at high or low risk of suffering a fatal arrhythmic event or SCD within a six-month time frame.

Vicor's PD2i Cardiac Analyzer addresses a significant health care issue involving a patient cohort of at least 12,000,000 patients. This patient cohort is composed of the MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II)/SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) patient population. Many in this patient cohort may need an ICD (Implantable Cardioverter Defibrillator) as life saving therapy. However, recent registry studies have noted that over 70% of implanted ICDs never have an appropriate firing. This over-implantation has led to a substantial and unnecessary medical cost burden. Over-implantation of this patient cohort also puts patients at risk because of the complications that can accompany implantation surgery. There is also the risk of not identifying patients who need this life-saving therapy because current criteria do not provide physicians the ability to accurately risk stratify their patients.

The PD2i Cardiac Analyzer contains the patented PD2i algorithm which provides a method for evaluating electrophysiological potentials with a high sensitivity and high specificity used to predict future pathological events i.e. fatal cardiac arrhythmias. The PD2i algorithm detects deterministic, low-dimensional excursions in nonstationary heartbeat intervals. The PD2i algorithm uses an analytic measure that is deterministic and nonlinear. It is based on caused variation in data; does not require data stationarity and actually tracks nonstationary changes in the data. It is sensitive to chaotic as well as nonchaotic, linear data.

The mission of the Vicor drug discovery platform is to focus on the pre-clinical and early clinical development of specific naturally occurring peptides and proteins derived from "state-dependent" physiologies that will revolutionize the treatment of an array of human diseases.

For more information visit the Vicor Technologies web site

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i Cardiac Analyzer for military and civilian applications, our ability continue to receive financing sufficient to complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 08-08

Contact Information